TheraTalks Episode 4 Explores Quality, Compliance & Resilient Supply Chains in the Pharmaceutical Industry
August 14th, 2026 – Thera Health Policy & Access is pleased to announce the release of Episode 4 of TheraTalks, the interview series dedicated to engaging healthcare leaders, policy experts, regulators, and industry innovators in meaningful conversations about the issues shaping the future of healthcare in Latin America and beyond.
This latest episode features a conversation between José Luis Cárdenas Tomažič, Founder & Managing Director of Thera Health Policy & Access, and Carmen Polanco, Senior Strategic Advisor for Quality & Compliance at Thera Health Policy & Access and a globally recognized pharmaceutical quality leader with more than 25 years of experience in quality systems, compliance, manufacturing operations, inspections, and supply chain management.
During the interview, José Luis and Carmen discuss how the pharmaceutical industry must evolve beyond traditional compliance-driven approaches to quality management in order to address the increasing complexity of medicines, manufacturing technologies, and global supply networks. The conversation highlights the need for predictive, risk-based, and continuously improving quality systems capable of supporting innovation while safeguarding patient access to safe and effective therapies.
A central theme of the discussion is the evolution of pharmaceutical quality systems. Carmen explains how compliance with Good Manufacturing Practices (GMPs), while essential, is no longer sufficient on its own to ensure sustainable quality performance. Instead, organizations must embrace more mature quality management models that integrate risk management, data-driven decision-making, knowledge management, and continuous improvement throughout the product lifecycle.
The episode also explores the critical role of quality culture and organizational maturity. The speakers examine how leadership commitment, employee engagement, and cross-functional collaboration contribute to an organization’s ability to anticipate risks, prevent quality failures, and build operational resilience. They emphasize that quality should not be viewed solely as a regulatory obligation, but as a strategic capability that strengthens competitiveness and supports long-term business success.
Another important topic addressed during the interview is the growing need for resilient pharmaceutical supply chains. As supply networks become increasingly globalized and fragmented, the ability to effectively oversee suppliers, manage risks, and ensure business continuity has become a critical priority for both industry and healthcare systems. The discussion highlights the importance of incorporating quality maturity, compliance history, and risk management considerations into procurement and supply chain decisions to prevent shortages and ensure uninterrupted patient access to medicines.
The conversation further examines the challenges facing regulatory systems across Latin America. José Luis and Carmen discuss the importance of strengthening regulatory capabilities, promoting convergence initiatives, and expanding opportunities for international collaboration and knowledge sharing. They note that regulatory authorities must continue adapting to scientific and technological advances while maintaining effective oversight of increasingly sophisticated healthcare products and manufacturing processes.
In addition, the interview addresses the unique quality and regulatory challenges associated with biological products and advanced therapies. These innovative technologies often require more complex manufacturing processes, specialized facilities, and enhanced regulatory oversight. The discussion highlights the need for stronger quality systems and greater regulatory preparedness to support the development and commercialization of next-generation therapies across the region.
Looking ahead, Carmen Polanco shares her perspective on how both industry and academia can contribute to preparing the next generation of pharmaceutical professionals. She emphasizes the importance of interdisciplinary education, stronger integration between scientific and engineering disciplines, and the development of practical skills that enable future leaders to navigate an increasingly complex and technology-driven pharmaceutical ecosystem.
“Quality and compliance should not be viewed simply as regulatory requirements. They are strategic enablers of innovation, patient safety, supply continuity, and trust across the healthcare ecosystem. Organizations that embrace quality maturity and proactive risk management will be better positioned to meet the challenges of the future,” said José Luis Cárdenas Tomažič.
Watch the full interview here:
Watch TheraTalks Episode 4
About the Guest
Carmen Polanco serves as Senior Strategic Advisor for Quality & Compliance at Thera Health Policy & Access. Throughout her distinguished career, she has held senior leadership positions within the global pharmaceutical industry, leading initiatives across quality systems, regulatory compliance, manufacturing operations, inspections, supplier quality, and supply chain management. She is widely recognized for her expertise in pharmaceutical quality excellence, quality culture, compliance strategy, organizational quality maturity, and risk management.
About Thera Health Policy & Access
Thera Health Policy & Access is a specialized consultancy and Think & Do Tank focused on health policy, market access, healthcare regulation, public affairs, strategic intelligence, and healthcare system transformation. Through evidence-based analysis, stakeholder engagement, and multidisciplinary expertise, Thera supports organizations in navigating complex healthcare environments and advancing sustainable solutions that improve patient access and health outcomes across Latin America.
